Recce Pharmaceuticals Director Increases Stake with New Options

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Recce Pharmaceuticals Ltd. announced a change in the interests of Director Dr. John Prendergast, who acquired 2,650,000 unlisted options under the company’s Employee Incentive Plan. These options have an estimated value of $0.244 each, calculated using the Black Scholes valuation method, highlighting the director’s increased stake in the company.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.